CEL-SCI (NYSE:CVM) & Inhibikase Therapeutics (NYSE:IKT) Head-To-Head Comparison

CEL-SCI (NYSE:CVM) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends.

Valuation and Earnings

This table compares CEL-SCI and Inhibikase Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CEL-SCI	N/A	N/A	-$32.19 million	($0.68)	-2.21
Inhibikase Therapeutics	$260,000.00	33.90	-$19.03 million	($3.56)	-0.38

Inhibikase Therapeutics has higher revenue and earnings than CEL-SCI. CEL-SCI is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CEL-SCI has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Profitability

This table compares CEL-SCI and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CEL-SCI	N/A	-204.28%	-95.72%
Inhibikase Therapeutics	-5,886.15%	-107.54%	-91.82%

Analyst Recommendations

This is a summary of current ratings and recommmendations for CEL-SCI and Inhibikase Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CEL-SCI	0	0	0	0	N/A
Inhibikase Therapeutics	0	0	1	0	3.00

Inhibikase Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 1,885.29%. Given Inhibikase Therapeutics’ higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than CEL-SCI.

Insider and Institutional Ownership

12.1% of CEL-SCI shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 14.1% of CEL-SCI shares are owned by insiders. Comparatively, 20.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats CEL-SCI on 9 of the 12 factors compared between the two stocks.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.